Casdin Capital, LLC Gritstone Bio, Inc. Transaction History

Casdin Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$2.63 - $8.09 $4.87 Million - $15 Million	-1,850,373 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$5.69 - $8.17 $2.39 Million - $3.43 Million	-419,627 Reduced 18.49%	1,850,373 $12.3 Million
Q1 2020 May 15, 2020	BUY	$5.47 - $11.3 $601,700 - $1.24 Million	110,000 Added 5.09%	2,270,000 $13.2 Million
Q4 2019 Feb 14, 2020	BUY	$7.07 - $11.61 $2.76 Million - $4.53 Million	390,000 Added 22.03%	2,160,000 $19.4 Million
Q3 2019 Nov 12, 2019	BUY	$8.45 - $12.28 $15 Million - $21.7 Million	1,770,000 New	1,770,000 $19.7 Billion
Q3 2019 Nov 12, 2019	SELL	$8.45 - $12.28 $15 Million - $21.7 Million	-1,770,000 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$9.2 - $15.7 $5.97 Million - $10.2 Million	649,414 Added 57.95%	1,770,000 $0
Q1 2019 May 15, 2019	BUY	$9.97 - $18.96 $3.99 Million - $7.58 Million	400,000 Added 55.51%	1,120,586 $14.9 Million
Q3 2018 Nov 14, 2018	BUY	$14.24 - $14.24 $10.3 Million - $10.3 Million	720,586 New	720,586 $10.3 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.